July 6, 2020 -- CSL Behring has enrolled the first patient in its phase clinical II study to assess the safety and efficacy of CSL312 (garadacimab, factor XIIa-inhibitory monoclonal antibody) to treat respiratory distress associated with COVID-19.
The multicenter, double-blind, placebo-controlled study will enroll approximately 124 adult patients with COVID-19. CSL312 will be administered intravenously in combination with standard-of-care treatments.
CSL312 inhibits the plasma protein, Factor XIIa, to prevent the molecular cascade leading to edema formation. It is also under clinical development as a once-monthly subcutaneous prophylactic treatment for attacks related to hereditary angioedema.
In addition to the study of CSL312, the company is also: